William Blair Has Pessimistic Outlook of Exagen Q2 Earnings

Exagen Inc. (NASDAQ:XGN) – William Blair dropped their Q2 2025 earnings per share estimates for Exagen in a research report issued to clients and investors on Monday, May 5th. William Blair analyst A. Brackmann now anticipates that the company will post earnings of ($0.18) per share for the quarter, down from their previous estimate of ($0.16). William Blair has a “Outperform” rating on the stock. The consensus estimate for Exagen’s current full-year earnings is ($0.88) per share. William Blair also issued estimates for Exagen’s Q3 2025 earnings at ($0.14) EPS, Q4 2025 earnings at ($0.09) EPS, FY2025 earnings at ($0.61) EPS and FY2026 earnings at ($0.25) EPS.

A number of other equities research analysts have also recently commented on XGN. BTIG Research reaffirmed a “buy” rating on shares of Exagen in a report on Wednesday. Cantor Fitzgerald restated an “overweight” rating and issued a $8.00 target price on shares of Exagen in a research note on Monday, January 13th.

Exagen Stock Down 7.3 %

XGN opened at $5.71 on Thursday. Exagen has a twelve month low of $1.38 and a twelve month high of $7.20. The company’s 50-day moving average price is $4.54 and its two-hundred day moving average price is $4.11. The stock has a market cap of $102.79 million, a price-to-earnings ratio of -6.07 and a beta of 1.50. The company has a quick ratio of 4.05, a current ratio of 4.05 and a debt-to-equity ratio of 1.54.

Exagen (NASDAQ:XGN) last issued its quarterly earnings results on Monday, May 12th. The company reported ($0.20) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.20). Exagen had a negative net margin of 30.36% and a negative return on equity of 92.58%. The company had revenue of $15.50 million for the quarter, compared to the consensus estimate of $14.55 million. During the same period in the previous year, the firm earned ($0.19) EPS.

Institutional Trading of Exagen

Hedge funds and other institutional investors have recently modified their holdings of the business. Corient Private Wealth LLC bought a new stake in Exagen during the 4th quarter valued at $45,000. Virtu Financial LLC purchased a new position in shares of Exagen in the fourth quarter valued at $46,000. Marshall Wace LLP bought a new stake in shares of Exagen during the 4th quarter valued at $66,000. Northern Trust Corp lifted its holdings in Exagen by 16.7% during the 4th quarter. Northern Trust Corp now owns 18,375 shares of the company’s stock worth $75,000 after purchasing an additional 2,630 shares in the last quarter. Finally, Huntleigh Advisors Inc. boosted its stake in Exagen by 16.8% in the 1st quarter. Huntleigh Advisors Inc. now owns 83,108 shares of the company’s stock worth $298,000 after purchasing an additional 11,939 shares during the period. Institutional investors own 75.25% of the company’s stock.

Exagen Company Profile

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).